homepage hero
Scroll down
Stasis to peristalsis

Enhanced colonic peristalsis is possible with Motegrity, the only FDA-approved selective serotonin type 4 (5-HT4) receptor agonist for adults with CIC.1-4

Discover the Motegrity difference

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Motegrity is a GI prokinetic that enhances colonic peristalsis (i.e. HAPCs), which increases bowel motility

In a pharmacodynamic study in patients with CIC, a single 2 mg dose of Motegrity increased the number of HAPCs during the first 12 hours vs. an osmotic laxative treatment.1
Treatment with Motegrity 4 mg once daily (2X max recommended dose of 2 mg) for 7 days increased the amplitude of HAPCs in healthy subjects without affecting colonic phasic activity vs. placebo.1

See mechanism of action

HAPCs=high amplitude propagating contractions

Help your patients save on Motegrity

With the Motegrity savings card, eligible patients can pay as little as $15* per 30-day fill or $45* per 90-day fill.

Find out more
Motegrity savings card

*Up to $90 max benefit per 30-day prescription; $270 max benefit per 90-day prescription. Terms and conditions apply. See link above for details.

Calendar icon

Clinical Efficacy

View the results established in 6 clinical trials in 2484 patients with CIC.1

See trial data
Bottle icon

Request Samples

Interested in receiving samples of Motegrity?

Request samples
Map icon

Local Formulary Coverage

Patient access coverage tool

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for persistent worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if their depression is persistently worse, or they experience emerging suicidal thoughts or behaviors.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

INDICATION

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

References:

1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Shire LLC. 2. Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Am J Gastroenterol. 2014;109(6):887-894. 3. Miner PB, Camilleri M, Burton D, et al. Neurogastroenterol Motil. 2016;28(9):1341-1348. 4. Enterostasis. Stedman's Online. https://stedmansonline.com/‌content.aspx‌?term=‌ENTEROSTASIS. Accessed February 25, 2019.

Copyright © 2020 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 1-800-828-2088. Motegrity is a trademark or registered trademark of Shire LLC, a Takeda company. TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.
US-PRU-0133v1.0  09/20

All content of this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda makes reasonable efforts to include accurate, up-to-date information on this site, Takeda makes no warranties or representations as to its accuracy. Takeda assumes no liability for any errors or omissions in the content of this site. The information on this site is not intended to make a diagnosis or to take the place of talking to a US health care professional.